Advances in the mouse models of myeloid leukemia_Journal of Biomedical Engineering

Authors：

GE Chentao ,  FU Caiyun

College of Life Sciences and Medicine, Zhejiang Sci-Tech University, Hangzhou 310018, P.R.China;

Corresponding author：

Keywords：

myeloid leukemia; mouse strains; xenograft models; patient derived xenograft model

DOI：

10.7507/1001-5515.201903012

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Mouse animal models are the most commonly used experimental tools in scientific research, which have been widely favored by researchers. The animal model of mouse leukemia appeared in the 1930s. During the past 90 years, researchers have developed various types of mouse leukemia models to simulate the development and treatment of human leukemia in order to promote effectively the elucidation of the molecular mechanism of leukemia' development and progression, as well as the development of targeted drugs for the treatment of leukemia. Considering that to myeloid leukemia, especially acute myeloid leukemia, there currently is no good clinical treatment, it is urgent to clarify its new molecular mechanism and develop new therapeutic targets. This review focuses on the various types of mouse models about myeloid leukemia used commonly in recent years, including mouse strains, myeloid leukemia cell types, and modeling methods, which are expected to provide a reference for relevant researchers to select animal models during myeloid leukemia research.

Citation： GE Chentao, FU Caiyun. Advances in the mouse models of myeloid leukemia. Journal of Biomedical Engineering, 2019, 36(5): 885-892. doi: 10.7507/1001-5515.201903012 Copy

1.	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2.	Dameshek W. Chronic lymphocytic leukemia—an accumulative disease of immunolgically incompetent lymphocytes. Blood, 1967, 29(4 Suppl): 566-584.
3.	Nugent E. Humblebees vs. field-mice. Science, 1883, 2(35): 470.
4.	Richter M N, Macdowell E C. Studies on leukemia in mice: I. The experimental transmission of leukemia. J Exp Med, 1930, 51(4): 659-673.
5.	Congdon C C, Gengozian N, Makinodan T. Agglutinin production in normal, sublethally irradiated, and lethally irradiated mice treated with mouse bone marrow. J Immunol, 1956, 77(4): 250-256.
6.	Burchenal J H, Webber L F, Johnston S F. Mechanisms of amethopterin resistance in leukemia. II. Effect of cortisone on sensitive and resistant mouse leukemias. Proc Soc Exp Biol Med, 1951, 78(1): 352-354.
7.	Smith K M, Fagan P C, Pomari E, et al. Antitumor activity of entrectinib, a Pan-TRK, ROS1, and ALK inhibitor, in ETV6-NTRK3-positive acute myeloid leukemia. Mol Cancer Ther, 2018, 17(2): 455-463.
8.	Gao X N, Yan F, Lin J, et al. AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation. Leukemia, 2015, 29(8): 1730-1740.
9.	Shan Zhiling, Zhu Xinyu, Ma Pengpeng, et al. PML(NLS-) protein: A novel marker for the early diagnosis of acute promyelocytic leukemia. Mol Med Rep, 2017, 16(4): 5418-5424.
10.	Green A S, Maciel T T, Hospital M A, et al. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv, 2015, 1(8): e1500221-e1500233.
11.	Liyanage S U, Hurren R, Voisin V, et al. Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. Blood, 2017, 129(19): 2657-2666.
12.	Floc'h N, Ashton S, Taylor P, et al. Optimizing therapeutic effect of Aurora B inhibition in acute myeloid leukemia with AZD2811 nanoparticles. Mol Cancer Ther, 2017, 16(6): 1031-1040.
13.	Li Jingdong, Zi Youmei, Wang Wanling, et al. Long noncoding RNA MEG3 inhibits cell proliferation and metastasis in chronic myeloid leukemia via targeting miR-184. Oncol Res, 2018, 26(2): 297-305.
14.	Gu Yueli, Si Jinchun, Xiao Xichun, et al. miR-92a inhibits proliferation and induces apoptosis by regulating methylenetetrahydrofolate dehydrogenase 2(MTHFD2) expression in acute myeloid leukemia. Oncol Res, 2017, 25(7): 1069-1079.
15.	Zhu Baomin, Zhang Huanying, Yu Lianling. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation. Biomed Pharmacother, 2017, 86: 547-554.
16.	Chen L T, Chen C T, Jiaang W T, et al. BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT-driven myeloid leukemia. Mol Cancer Ther, 2016, 15(10): 2323-2333.
17.	Heo S K, Noh E K, Kim J Y, et al. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Sci Rep, 2017, 7(1): 1-12.
18.	Ishikawa Y, Gamo K, Yabuki M, et al. A novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to transdifferentiation and impaired growth of AML cells. Mol Cancer Ther, 2017, 16(2): 273-284.
19.	Morgado-Palacin I, Day A, Murga M, et al. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. Sci Signal, 2016, 9(445): ra91-ra107.
20.	Maes T, Mascaro C, Tirapu I, et al. ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell, 2018, 33(3): 495-511.
21.	Puente-Moncada N, Costales P, Antolin I, et al. Inhibition of FLT3 and PIM kinases by EC-70124 exerts potent activity in preclinical models of acute myeloid leukemia. Mol Cancer Ther, 2018, 17(3): 614-624.
22.	Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs, 2017, 35(5): 556-565.
23.	Chen Meiyu, Xiong Fei, Ma Liang, et al. Inhibitory effect of magnetic Fe₃O₄ nanoparticles coloaded with homoharringtonine on human leukemia cells in vivo and in vitro. Int J Nanomedicine, 2016, 11: 4413-4422.
24.	Park G T, Heo J R, Kim S U, et al. The growth of K562 human leukemia cells was inhibited by therapeutic neural stem cells in cellular and xenograft mouse models. Cytotherapy, 2018, 20(9): 1191-1201.
25.	Bellavia D, Raimondo S, Calabrese G, et al. Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth. Theranostics, 2017, 7(5): 1333-1345.
26.	Liu Xuesong, Wang Beilei, Chen Cheng, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur J Med Chem, 2018, 160: 61-81.
27.	Endo A, Tomizawa D, Aoki Y, et al. EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway. Cancer Sci, 2016, 107(12): 1745-1754.
28.	Carretta M, De Boer B, Jaques J, et al. Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models. Exp Hematol, 2017, 51: 36-46.
29.	McGill C M, Brown T J, Cheng Y Y, et al. Therapeutic effect of blueberry extracts for acute myeloid leukemia. Int J Biopharm Sci, 2018, 1(1): 102-115.
30.	Ferreira A K, Santana-Lemos B, Rego E M, et al. Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects. Br J Cancer, 2013, 109(11): 2819-2828.
31.	Zhang Feifei, Liu Xiaoye, Chen Chiqi, et al. CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27(kip1) signaling. Haematologica, 2017, 102(4): 707-718.
32.	Nóbrega-Pereira S, Caiado F, Carvalho T A, et al. VEGFR2-mediated reprogramming of mitochondrial metabolism regulates the sensitivity of acute myeloid leukemia to chemotherapy. Cancer Res, 2018, 78(3): 731-741.
33.	Yoshimi A, Balasis M E, Vedder A, et al. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood, 2017, 130(4): 397-407.
34.	Torello C O, Shiraishi R N, Della Via F I, et al. Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model. Cancer Lett, 2018, 414: 116-126.
35.	Jin Yanxia, Yang Qian, Liang Li, et al. Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway. J Exp Clin Cancer Res, 2018, 37(1): 277-289.
36.	Battula V L, Le P M, Sun J C, et al. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight, 2017, 2(13): e90036-e90053.
37.	Cartellieri M, Feldmann A, Koristka S, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J, 2016, 6(8): e458-e475.
38.	Carter B Z, Mak P Y, Wang X, et al. Focal adhesion kinase as a potential target in AML and MDS. Mol Cancer Ther, 2017, 16(6): 1133-1144.
39.	Saland E, Boutzen H, Castellano R, et al. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer J, 2015, 5: e297-e304.
40.	Tashiro H, Sauer T, Shum T, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Molecular Therapy, 2017, 25(9): 2202-2213.
41.	Chen Jiajie, Zhou Wei, Cai Nan, et al. In vivo murine model of leukemia cell-induced spinal bone destruction. Biomed Res Int, 2017, 2017: 1-6.
42.	Zhang C C, Yan Z, Pascual B, et al. Gemtuzumab ozogamicin (GO) inclusion to induction chemotherapy eliminates leukemic initiating cells and significantly improves survival in mouse models of acute myeloid leukemia. Neoplasia, 2018, 20(1): 1-11.
43.	Saenz D T, Fiskus W, Manshouri T, et al. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia, 2017, 31(3): 678-687.
44.	Xu Xuefen, Zhang Xiaobo, Zhang Yi, et al. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-kappa B inactivation. Sci Rep, 2017, 7: 1-15.
45.	Morita M, Nishinaka Y, Kato I, et al. Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia. Int J Hematol, 2017, 105(3): 335-340.
46.	Shen Na, Yan Fei, Pang Jiuxia, et al. Inactivation of receptor tyrosine kinases reverts aberrant DNA methylation in acute myeloid leukemia. Clin Cancer Res, 2017, 23(20): 6254-6266.
47.	Deng Rong, Shen Na, Yang Yang, et al. Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy. Biomaterials, 2018, 167: 80-90.
48.	Her Z, Yong K S, Paramasivam K, et al. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia. J Hematol Oncol, 2017, 10(1): 162-175.
49.	Paczulla A M, Dirnhofer S, Konantz M A, et al. Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice. Haematologica, 2017, 102(5): 854-864.
50.	Venton G, Perez-Alea M, Baier C, et al. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J, 2016, 6(9): e469-e477.
51.	Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci, 2016, 107(10): 1422-1429.
52.	Pomeroy E J, Lee L A, Lee R D W, et al. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene, 2017, 36(23): 3263-3273.
53.	Peterson L F, Lo M C, Liu Yihong, et al. Induction of p53 suppresses chronic myeloid leukemia. Leuk Lymphoma, 2017, 58(9): 2165-2175.
54.	Lin H, Woolfson A, Jiang X. New mouse models to investigate the efficacy of drug combinations in human chronic myeloid leukemia. Methods Mol Biol, 2016, 1465: 187-205.
55.	Jin Yanli, Yao Yiwu, Chen Li, et al. Depletion of gamma-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with imatinib. Theranostics, 2016, 6(11): 1947-1962.
56.	Laouedj M, Tardif M R, Gil L, et al. S100A9 induces differentiation of acute myeloid leukemia cells through TLR4. Blood, 2017, 129(14): 1980-1990.
57.	Minzel W, Venkatachalam A, Fink A, et al. Small molecules co-targeting CKI alpha and the transcriptional kinases CDK7/9 control AML in preclinical models. Cell, 2018, 175(1): 171-185.
58.	Long J, Fang W Y, Chang L, et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia, 2017, 31(12): 2761-2770.
59.	Liang K, Volk A G, Haug J S, et al. Therapeutic targeting of MLL degradation pathways in MLL-rearranged leukemia. Cell, 2017, 168(1/2): 59-72.
60.	Lopez-Millan B, Sanchez-Martinez D, Roca-Ho H, et al. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia, 2019, 33: 1557-1569.
61.	Godley L A. Inherited predisposition to acute myeloid leukemia. Semin Hematol, 2014, 51(4): 306-321.
62.	Polprasert C, Schulze I, Sekeres M A, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell, 2015, 27(5): 658-670.
63.	Zhang M Y, Churpek J E, Keel S B, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet, 2015, 47(2): 180-185.
64.	Lindsley R C, Mar B G, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood, 2015, 125(9): 1367-1376.
65.	Basova P, Pospisil V, Savvulidi F, et al. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene, 2014, 33(39): 4735-4745.
66.	Omidvar N, Kogan S, Beurlet S, et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res, 2007, 67(24): 11657-11667.
67.	Tsai C H, Hou H A, Tang J L, et al. Prognostic impacts and dynamic changes of cohesin complex gene mutations in De Novo acute myeloid leukemia. Blood, 2017, 130(1): 663-669.
68.	Mullenders J, Aranda-Orgilles B, Lhoumaud P, et al. Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. J Exp Med, 2015, 212(11): 1833-1850.
69.	Harada N, Hasegawa A, Hirano I, et al. GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice. Cancer Sci, 2019, 110(4): 1183-1193.
70.	Kaur M, Drake A C, Hu Guangan, et al. Induction and therapeutic targeting of human NPM1c(+) myeloid leukemia in the presence of autologous immune system in mice. J Immunol, 2019, 202(6): 1885-1894.
71.	Joslin J M, Fernald A A, Tennant T R, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood, 2007, 110(2): 719-726.
72.	Lu E P, Mclellan M, Ding Li, et al. Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. Blood, 2014, 124(26): 3887-3895.
73.	Bernard N, Devevey L, Jacquemont C, et al. A new model of pre-B acute lymphoblastic leukemia chemically induced in rats. Exp Hematol, 2005, 33(10): 1130-1139.
74.	Sugiyama T, Osaka M, Koami K, et al. 7,12-DMBA-induced rat leukemia: a review with insights into future research. Leuk Res, 2002, 26(12): 1053-1068.
75.	Mak I W, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res, 2014, 6(2): 114-118.
76.	Perrin S. Preclinical research: Make mouse studies work. Nature, 2014, 507(7493): 423-425.

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2018, 68(6): 394-424.
2. Dameshek W. Chronic lymphocytic leukemia—an accumulative disease of immunolgically incompetent lymphocytes. Blood, 1967, 29(4 Suppl): 566-584.
3. Nugent E. Humblebees vs. field-mice. Science, 1883, 2(35): 470.
4. Richter M N, Macdowell E C. Studies on leukemia in mice: I. The experimental transmission of leukemia. J Exp Med, 1930, 51(4): 659-673.
5. Congdon C C, Gengozian N, Makinodan T. Agglutinin production in normal, sublethally irradiated, and lethally irradiated mice treated with mouse bone marrow. J Immunol, 1956, 77(4): 250-256.
6. Burchenal J H, Webber L F, Johnston S F. Mechanisms of amethopterin resistance in leukemia. II. Effect of cortisone on sensitive and resistant mouse leukemias. Proc Soc Exp Biol Med, 1951, 78(1): 352-354.
7. Smith K M, Fagan P C, Pomari E, et al. Antitumor activity of entrectinib, a Pan-TRK, ROS1, and ALK inhibitor, in ETV6-NTRK3-positive acute myeloid leukemia. Mol Cancer Ther, 2018, 17(2): 455-463.
8. Gao X N, Yan F, Lin J, et al. AML1/ETO cooperates with HIF1alpha to promote leukemogenesis through DNMT3a transactivation. Leukemia, 2015, 29(8): 1730-1740.
9. Shan Zhiling, Zhu Xinyu, Ma Pengpeng, et al. PML(NLS-) protein: A novel marker for the early diagnosis of acute promyelocytic leukemia. Mol Med Rep, 2017, 16(4): 5418-5424.
10. Green A S, Maciel T T, Hospital M A, et al. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia. Sci Adv, 2015, 1(8): e1500221-e1500233.
11. Liyanage S U, Hurren R, Voisin V, et al. Leveraging increased cytoplasmic nucleoside kinase activity to target mtDNA and oxidative phosphorylation in AML. Blood, 2017, 129(19): 2657-2666.
12. Floc'h N, Ashton S, Taylor P, et al. Optimizing therapeutic effect of Aurora B inhibition in acute myeloid leukemia with AZD2811 nanoparticles. Mol Cancer Ther, 2017, 16(6): 1031-1040.
13. Li Jingdong, Zi Youmei, Wang Wanling, et al. Long noncoding RNA MEG3 inhibits cell proliferation and metastasis in chronic myeloid leukemia via targeting miR-184. Oncol Res, 2018, 26(2): 297-305.
14. Gu Yueli, Si Jinchun, Xiao Xichun, et al. miR-92a inhibits proliferation and induces apoptosis by regulating methylenetetrahydrofolate dehydrogenase 2(MTHFD2) expression in acute myeloid leukemia. Oncol Res, 2017, 25(7): 1069-1079.
15. Zhu Baomin, Zhang Huanying, Yu Lianling. Novel transferrin modified and doxorubicin loaded Pluronic 85/lipid-polymeric nanoparticles for the treatment of leukemia: In vitro and in vivo therapeutic effect evaluation. Biomed Pharmacother, 2017, 86: 547-554.
16. Chen L T, Chen C T, Jiaang W T, et al. BPR1J373, an oral multiple tyrosine kinase inhibitor, targets c-KIT for the treatment of c-KIT-driven myeloid leukemia. Mol Cancer Ther, 2016, 15(10): 2323-2333.
17. Heo S K, Noh E K, Kim J Y, et al. Targeting c-KIT (CD117) by dasatinib and radotinib promotes acute myeloid leukemia cell death. Sci Rep, 2017, 7(1): 1-12.
18. Ishikawa Y, Gamo K, Yabuki M, et al. A novel LSD1 inhibitor T-3775440 disrupts GFI1B-containing complex leading to transdifferentiation and impaired growth of AML cells. Mol Cancer Ther, 2017, 16(2): 273-284.
19. Morgado-Palacin I, Day A, Murga M, et al. Targeting the kinase activities of ATR and ATM exhibits antitumoral activity in mouse models of MLL-rearranged AML. Sci Signal, 2016, 9(445): ra91-ra107.
20. Maes T, Mascaro C, Tirapu I, et al. ORY-1001, a potent and selective covalent KDM1A inhibitor, for the treatment of acute leukemia. Cancer Cell, 2018, 33(3): 495-511.
21. Puente-Moncada N, Costales P, Antolin I, et al. Inhibition of FLT3 and PIM kinases by EC-70124 exerts potent activity in preclinical models of acute myeloid leukemia. Mol Cancer Ther, 2018, 17(3): 614-624.
22. Mori M, Kaneko N, Ueno Y, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs, 2017, 35(5): 556-565.
23. Chen Meiyu, Xiong Fei, Ma Liang, et al. Inhibitory effect of magnetic Fe₃O₄ nanoparticles coloaded with homoharringtonine on human leukemia cells in vivo and in vitro. Int J Nanomedicine, 2016, 11: 4413-4422.
24. Park G T, Heo J R, Kim S U, et al. The growth of K562 human leukemia cells was inhibited by therapeutic neural stem cells in cellular and xenograft mouse models. Cytotherapy, 2018, 20(9): 1191-1201.
25. Bellavia D, Raimondo S, Calabrese G, et al. Interleukin 3-receptor targeted exosomes inhibit in vitro and in vivo chronic myelogenous leukemia cell growth. Theranostics, 2017, 7(5): 1333-1345.
26. Liu Xuesong, Wang Beilei, Chen Cheng, et al. Discovery of (E)-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thio)propanamide (CHMFL-ABL-121) as a highly potent ABL kinase inhibitor capable of overcoming a variety of ABL mutants including T315I for chronic myeloid leukemia. Eur J Med Chem, 2018, 160: 61-81.
27. Endo A, Tomizawa D, Aoki Y, et al. EWSR1/ELF5 induces acute myeloid leukemia by inhibiting p53/p21 pathway. Cancer Sci, 2016, 107(12): 1745-1754.
28. Carretta M, De Boer B, Jaques J, et al. Genetically engineered mesenchymal stromal cells produce IL-3 and TPO to further improve human scaffold-based xenograft models. Exp Hematol, 2017, 51: 36-46.
29. McGill C M, Brown T J, Cheng Y Y, et al. Therapeutic effect of blueberry extracts for acute myeloid leukemia. Int J Biopharm Sci, 2018, 1(1): 102-115.
30. Ferreira A K, Santana-Lemos B, Rego E M, et al. Synthetic phosphoethanolamine has in vitro and in vivo anti-leukemia effects. Br J Cancer, 2013, 109(11): 2819-2828.
31. Zhang Feifei, Liu Xiaoye, Chen Chiqi, et al. CD244 maintains the proliferation ability of leukemia initiating cells through SHP-2/p27(kip1) signaling. Haematologica, 2017, 102(4): 707-718.
32. Nóbrega-Pereira S, Caiado F, Carvalho T A, et al. VEGFR2-mediated reprogramming of mitochondrial metabolism regulates the sensitivity of acute myeloid leukemia to chemotherapy. Cancer Res, 2018, 78(3): 731-741.
33. Yoshimi A, Balasis M E, Vedder A, et al. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Blood, 2017, 130(4): 397-407.
34. Torello C O, Shiraishi R N, Della Via F I, et al. Reactive oxygen species production triggers green tea-induced anti-leukaemic effects on acute promyelocytic leukaemia model. Cancer Lett, 2018, 414: 116-126.
35. Jin Yanxia, Yang Qian, Liang Li, et al. Compound kushen injection suppresses human acute myeloid leukaemia by regulating the Prdxs/ROS/Trx1 signalling pathway. J Exp Clin Cancer Res, 2018, 37(1): 277-289.
36. Battula V L, Le P M, Sun J C, et al. AML-induced osteogenic differentiation in mesenchymal stromal cells supports leukemia growth. JCI Insight, 2017, 2(13): e90036-e90053.
37. Cartellieri M, Feldmann A, Koristka S, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J, 2016, 6(8): e458-e475.
38. Carter B Z, Mak P Y, Wang X, et al. Focal adhesion kinase as a potential target in AML and MDS. Mol Cancer Ther, 2017, 16(6): 1133-1144.
39. Saland E, Boutzen H, Castellano R, et al. A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Blood Cancer J, 2015, 5: e297-e304.
40. Tashiro H, Sauer T, Shum T, et al. Treatment of acute myeloid leukemia with T cells expressing chimeric antigen receptors directed to C-type lectin-like molecule 1. Molecular Therapy, 2017, 25(9): 2202-2213.
41. Chen Jiajie, Zhou Wei, Cai Nan, et al. In vivo murine model of leukemia cell-induced spinal bone destruction. Biomed Res Int, 2017, 2017: 1-6.
42. Zhang C C, Yan Z, Pascual B, et al. Gemtuzumab ozogamicin (GO) inclusion to induction chemotherapy eliminates leukemic initiating cells and significantly improves survival in mouse models of acute myeloid leukemia. Neoplasia, 2018, 20(1): 1-11.
43. Saenz D T, Fiskus W, Manshouri T, et al. BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells. Leukemia, 2017, 31(3): 678-687.
44. Xu Xuefen, Zhang Xiaobo, Zhang Yi, et al. Wogonin reversed resistant human myelogenous leukemia cells via inhibiting Nrf2 signaling by Stat3/NF-kappa B inactivation. Sci Rep, 2017, 7: 1-15.
45. Morita M, Nishinaka Y, Kato I, et al. Dasatinib induces autophagy in mice with Bcr-Abl-positive leukemia. Int J Hematol, 2017, 105(3): 335-340.
46. Shen Na, Yan Fei, Pang Jiuxia, et al. Inactivation of receptor tyrosine kinases reverts aberrant DNA methylation in acute myeloid leukemia. Clin Cancer Res, 2017, 23(20): 6254-6266.
47. Deng Rong, Shen Na, Yang Yang, et al. Targeting epigenetic pathway with gold nanoparticles for acute myeloid leukemia therapy. Biomaterials, 2018, 167: 80-90.
48. Her Z, Yong K S, Paramasivam K, et al. An improved pre-clinical patient-derived liquid xenograft mouse model for acute myeloid leukemia. J Hematol Oncol, 2017, 10(1): 162-175.
49. Paczulla A M, Dirnhofer S, Konantz M A, et al. Long-term observation reveals high-frequency engraftment of human acute myeloid leukemia in immunodeficient mice. Haematologica, 2017, 102(5): 854-864.
50. Venton G, Perez-Alea M, Baier C, et al. Aldehyde dehydrogenases inhibition eradicates leukemia stem cells while sparing normal progenitors. Blood Cancer J, 2016, 6(9): e469-e477.
51. Fukushima N, Minami Y, Kakiuchi S, et al. Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells. Cancer Sci, 2016, 107(10): 1422-1429.
52. Pomeroy E J, Lee L A, Lee R D W, et al. Ras oncogene-independent activation of RALB signaling is a targetable mechanism of escape from NRAS(V12) oncogene addiction in acute myeloid leukemia. Oncogene, 2017, 36(23): 3263-3273.
53. Peterson L F, Lo M C, Liu Yihong, et al. Induction of p53 suppresses chronic myeloid leukemia. Leuk Lymphoma, 2017, 58(9): 2165-2175.
54. Lin H, Woolfson A, Jiang X. New mouse models to investigate the efficacy of drug combinations in human chronic myeloid leukemia. Methods Mol Biol, 2016, 1465: 187-205.
55. Jin Yanli, Yao Yiwu, Chen Li, et al. Depletion of gamma-catenin by histone deacetylase inhibition confers elimination of CML stem cells in combination with imatinib. Theranostics, 2016, 6(11): 1947-1962.
56. Laouedj M, Tardif M R, Gil L, et al. S100A9 induces differentiation of acute myeloid leukemia cells through TLR4. Blood, 2017, 129(14): 1980-1990.
57. Minzel W, Venkatachalam A, Fink A, et al. Small molecules co-targeting CKI alpha and the transcriptional kinases CDK7/9 control AML in preclinical models. Cell, 2018, 175(1): 171-185.
58. Long J, Fang W Y, Chang L, et al. Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response. Leukemia, 2017, 31(12): 2761-2770.
59. Liang K, Volk A G, Haug J S, et al. Therapeutic targeting of MLL degradation pathways in MLL-rearranged leukemia. Cell, 2017, 168(1/2): 59-72.
60. Lopez-Millan B, Sanchez-Martinez D, Roca-Ho H, et al. NG2 antigen is a therapeutic target for MLL-rearranged B-cell acute lymphoblastic leukemia. Leukemia, 2019, 33: 1557-1569.
61. Godley L A. Inherited predisposition to acute myeloid leukemia. Semin Hematol, 2014, 51(4): 306-321.
62. Polprasert C, Schulze I, Sekeres M A, et al. Inherited and somatic defects in DDX41 in myeloid neoplasms. Cancer Cell, 2015, 27(5): 658-670.
63. Zhang M Y, Churpek J E, Keel S B, et al. Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nat Genet, 2015, 47(2): 180-185.
64. Lindsley R C, Mar B G, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. Blood, 2015, 125(9): 1367-1376.
65. Basova P, Pospisil V, Savvulidi F, et al. Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene, 2014, 33(39): 4735-4745.
66. Omidvar N, Kogan S, Beurlet S, et al. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Cancer Res, 2007, 67(24): 11657-11667.
67. Tsai C H, Hou H A, Tang J L, et al. Prognostic impacts and dynamic changes of cohesin complex gene mutations in De Novo acute myeloid leukemia. Blood, 2017, 130(1): 663-669.
68. Mullenders J, Aranda-Orgilles B, Lhoumaud P, et al. Cohesin loss alters adult hematopoietic stem cell homeostasis, leading to myeloproliferative neoplasms. J Exp Med, 2015, 212(11): 1833-1850.
69. Harada N, Hasegawa A, Hirano I, et al. GATA2 hypomorphism induces chronic myelomonocytic leukemia in mice. Cancer Sci, 2019, 110(4): 1183-1193.
70. Kaur M, Drake A C, Hu Guangan, et al. Induction and therapeutic targeting of human NPM1c(+) myeloid leukemia in the presence of autologous immune system in mice. J Immunol, 2019, 202(6): 1885-1894.
71. Joslin J M, Fernald A A, Tennant T R, et al. Haploinsufficiency of EGR1, a candidate gene in the del(5q), leads to the development of myeloid disorders. Blood, 2007, 110(2): 719-726.
72. Lu E P, Mclellan M, Ding Li, et al. Caspase-9 is required for normal hematopoietic development and protection from alkylator-induced DNA damage in mice. Blood, 2014, 124(26): 3887-3895.
73. Bernard N, Devevey L, Jacquemont C, et al. A new model of pre-B acute lymphoblastic leukemia chemically induced in rats. Exp Hematol, 2005, 33(10): 1130-1139.
74. Sugiyama T, Osaka M, Koami K, et al. 7,12-DMBA-induced rat leukemia: a review with insights into future research. Leuk Res, 2002, 26(12): 1053-1068.
75. Mak I W, Evaniew N, Ghert M. Lost in translation: animal models and clinical trials in cancer treatment. Am J Transl Res, 2014, 6(2): 114-118.
76. Perrin S. Preclinical research: Make mouse studies work. Nature, 2014, 507(7493): 423-425.

Previous Article
A review of machine learning in tumor radiotherapy

Journal of Biomedical Engineering

Advances in the mouse models of myeloid leukemia

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Format

Content